Abstract
International guidelines on the prevention of migraine recommend the use of five main classes of medications: beta-blockers, antiepileptics, antidepressants (amitriptyline and venlafaxine), angiotensin receptor antagonists and botulinum toxin type A. Chronic tension-type headache (CTTH) guidelines are even more limiting and contain only amitriptyline, venlafaxine and mirtazapine. However, long-term intake of these medications is substantially limited by their tolerability issues. Moreover, most recommended medications cannot control the most frequently observed comorbidities, where depression plays the most important role in treatment selection, efficacy and long-term prognosis. This paper reviews the current migraine and CTTH prevention guidelines and complexities that physicians encounter with their use. The paper also includes a case series of treating chronic headache with a new multimodal antidepressant vortioxetine.
Highlights
Summary International guidelines on the prevention of migraine recommend the use of five main classes of medications: beta-blockers, antiepileptics, antidepressants, angiotensin receptor antagonists and botulinum toxin type A
This paper reviews the current migraine and Chronic tension-type headache (CTTH) prevention guidelines and complexities that physicians encounter with their use
Однако точное следование им у большого числа пациентов невозможно вследствие недостаточной эффективности препаратов, серьезных проблем с их переносимостью, а также наличия большого числа коморбидных заболеваний, самую важную роль для прогноза среди которых играет депрессия
Summary
Рекомендации по лечению хронической головной боли напряжения (ХГБН) ограничивают врача в еще большей степени и содержат только амитриптилин, венлафаксин и миртазапин. Также представлена серия случаев использования нового мультимодального антидепрессанта вортиоксетина в лечении хронической головной боли. Chronic tension-type headache (CTTH) guidelines are even more limiting and contain only amitriptyline, venlafaxine and mirtazapine.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
